恶性机械性肠梗阻临床诊疗

doi:10.16689/j.cnki.cn11－9349/r.2020.03.002

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (502 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要恶性机械性肠梗阻是晚期肿瘤常见并发症之一，通常以内科综合治疗为主。了解其病理生理机制（包括“不协调蠕动-组织水肿-不协调蠕动”及“分泌-扩张-分泌”恶性循环），明确梗阻的分类、亚型和完善肿瘤内科的系统评估（包括一般情况、脏器功能、肿瘤学评估、营养代谢及肠屏障功能）是其有效治疗的前提。治疗原则和目的是尽量减少，甚至解除机体肿瘤负荷，改善或根治肠梗阻所致不良症状、体征及肠功能异常，纠正水、电解质紊乱及营养代谢紊乱状态，最终改善患者生活质量及总生存。具体措施包括基础治疗、营养治疗和代谢调节、抗炎、减轻肠壁水肿、抑制消化道腺体分泌、修复肠道屏障及防治感染、抗肿瘤病因治疗及运动疗法、心理治疗。其中抗肿瘤病因治疗是临床中的难点，因恶性肠梗阻多伴随营养不良、一般情况差，难以耐受常规抗肿瘤治疗，抗肿瘤治疗上需兼顾肿瘤因素、营养状况及患者一般情况等，有效的抗肿瘤治疗是肠梗阻再通的基本保障。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	马怀幸
	李苏宜

Abstract：Malignant bowel obstruction is one of the common complications of advanced tumors. The treatment is mainly based on comprehensive medical methods. Understanding the pathophysiological mechanism (including “uncoordinated peristalsis-tissue edema-uncoordinated peristalsis” and “secretion-expansion-secretion” vicious circle), clarify the classification and subtype of obstruction and completing the systematic evaluation of oncology (including general conditions, organ function, oncology evaluation, nutritional metabolism and intestinal barrier function), are the prerequisites for its effective treatment. The principle and purpose of treatment are to minimize or even relieve the bodys tumor load, to improve or cure the adverse symptoms, signs and intestinal dysfunction caused by intestinal obstruction, to correct the state of water and electrolyte disorders and nutritional metabolism disorders, and ultimately to improve the patients quality of life and overall survival. Specific measures includes basic treatment, nutritional therapy and metabolic regulation, anti-inflammatory, reducing intestinal wall edema, inhibiting the secretion of glands in the digestive tract, repairing the intestinal barrier and preventing infection, anti-tumor etiology treatment and exercise therapy, psychological support. Anti-tumor etiological treatment is a clinical difficulty, because malignant bowel obstruction is often accompanied by malnutrition and poor general conditions, and it is difficult to tolerate conventional anti-tumor therapy. Anti-tumor therapy needs to take into account tumor factors, nutritional status and patients general conditions. Effective anti-tumor treatment is the basic guarantee for intestinal obstruction recanalization.

Key words： Tumor｜Malignant bowel obstruction｜Systematic evaluation｜Comprehensive treatment

基金资助:安徽省肿瘤医院青年基金（2020YJQN019）

通讯作者: 李苏宜，电子邮箱：njlisuyi@sina.com

引用本文:

马怀幸，李苏宜. 恶性机械性肠梗阻临床诊疗[J]. 肿瘤代谢与营养电子杂志, 2020, 7(3): 259-262.
Ma Huaixing, Li Suyi . Medical diagnosis and treatment of malignant bowel obstruction. Electron J Metab Nutr Cancer, 2020, 7(3): 259-262.

1.BOZZETTI F. The role of parenteral nutrition in patients with malignant bowel obstruction［J］. Support Care Cancer, 2019, 27(12):4393-4399.
2.PUJARA D, CHIANG Y J, CORMIER J N, et al. Selective approach for patients with advanced malignancy and gastrointestinal obstruction［J］. J Am Coll Surg, 2017, 225(1):53-59.
3.ARMAS I, BRANDO M, GUERREIRO I, et al. Incidental diagnosis of breast cancer in the pursuit of the treatment of intestinal obstruction［J］. Autops Case Rep, 2019, 9(1):e2018071.
4.ALESE O B, KIM S, CHEN Z, et al. Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction［J］. Cancer, 2015, 121(11):1772-1778.
5.李苏宜.慢性恶性机械性肠梗阻肿瘤内科处置思路及方法:文献复习和实践体会［C］.//中华医学会.2011全国肠内肠外营养学术会议论文集.2011:139-141.
6.DE BOER NL, HAGEMANS J A W, SCHULTZE B T A, et al. Acute malignant obstruction in patients with peritoneal carcinomatosis: The role of palliative surgery［J］. Eur J Surg Oncol, 2019, 45(3):389-393.
7.KROUSE R S. Malignant bowel obstruction［J］. J Surg Oncol, 2019, 120(1):74-77.
8.李世伟,马怀幸,李苏宜.ω-3多不饱和脂肪酸治疗癌性恶液质系统评价及荟萃分析［J］. 肠外与肠内营养, 2017, 24(1):28-32.
9.马怀幸,李苏宜. 肿瘤营养不良的内科治疗原理和原则［J］. 肿瘤学志, 2018, 24(9):849-855.
10.许佳伟,梁丙乾,郭建昇.奥曲肽联合常规治疗用于缓解恶性肠梗阻有效性与安全性的Meta分析［J］. 中国药房, 2019, 30(22):3138-3143.
11.KOH A, BCKHED F. From association to causality: the role of the gut microbiota and its functional products on host metabolism［J］. Mol Cell, 2020, 78(4):584-596.
12.TROHA K, AYRES J S. Metabolic adaptations to infections at the organismal level［J］. Trends Immunol, 2020, 41(2):113-125.
13.SCHULTHESS J, PANDEY S, CAPITANI M, et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages［J］. Immunity, 2019, 50(2):432-445.e7.
14.YANG S M, LI S Y, YU H B, et al. Metronomic chemotherapy with 5-fluorouracil and cisplatin for inoperable malignant bowel obstruction because of peritoneal dissemination from gastric cancer［J］. Curr Oncol, 2016, 23(3):e248-e252.
15.PENSON R T, VALENCIA R V, CIBULA D, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 Mutation (SOLO3):a randomized phase Ⅲ trial［J］. J Clin Oncol, 2020, 38(11):1164-1174.
16.WALSH C S. Latest clinical evidence of maintenance therapy in ovarian cancer［J］. Curr Opin Obstet Gynecol, 2020, 32(1):15-21.
17.BRAR G, SHAH M A. The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma ［J］. Therap Adv Gastroenterol, 2019, 12:1756284819869767.
18.BANG Y J, KANG Y K, CATENACCI D V, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: Results from the phase Ⅱ nonrandomized KEYNOTE-059 study［J］. Gastric Cancer, 2019, 22(4):828-837.
19.OLIVEIRA A F, BRETES L, FURTADO I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer［J］. Front Oncol, 2019, 9:396.
20.CHALABI M, CARDONA A, NAGARKAR D R, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hocanalyses of the OAK and POPLAR trials［J］. Ann Oncol, 2020, 31(4):525-531.